Crossmark

A phase I/II study of GLIF combination chemotherapy for taxane/platinum-refractory/resistant endometrial cancer (GOGO-EM2)

Crossref DOI link: https://doi.org/10.1007/s00280-018-3648-y

Published Online: 2018-07-20

Published Print: 2018-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tanaka, Yusuke

Ueda, Yutaka

Nakagawa, Satoshi

Matsuzaki, Shinya

Kobayashi, Eiji

Shiki, Yasuhiko

Nishio, Yukihiro

Takemura, Masahiko

Yamamoto, Toshiya

Sawada, Kenjiro

Tomimatsu, Takuji

Yoshino, Kiyoshi

Kimura, Tadashi
License Information

Text and Data Mining valid from 2018-07-20
More Information

Article History

Received: 8 June 2018

Accepted: 12 July 2018

First Online: 20 July 2018

Compliance with ethical standards

:

: The authors declare no conflicts of interest.

: Written informed consent was obtained from all patients.